355 related articles for article (PubMed ID: 25247952)
1. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
[TBL] [Abstract][Full Text] [Related]
2. Tumor load in patients with multiple myeloma: β₂-microglobulin levels versus low-dose whole-body CT.
Pfahler V; D'Anastasi M; Dürr HR; Schinner R; Ricke J; Baur-Melnyk A
Eur J Haematol; 2020 May; 104(5):383-389. PubMed ID: 31762076
[TBL] [Abstract][Full Text] [Related]
3. Whole-body MRI of multiple myeloma: comparison of different MRI sequences in assessment of different growth patterns.
Weininger M; Lauterbach B; Knop S; Pabst T; Kenn W; Hahn D; Beissert M
Eur J Radiol; 2009 Feb; 69(2):339-45. PubMed ID: 18096344
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?
Baur A; Stäbler A; Nagel D; Lamerz R; Bartl R; Hiller E; Wendtner C; Bachner F; Reiser M
Cancer; 2002 Sep; 95(6):1334-45. PubMed ID: 12216103
[TBL] [Abstract][Full Text] [Related]
5. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma.
Baur-Melnyk A; Buhmann S; Becker C; Schoenberg SO; Lang N; Bartl R; Reiser MF
AJR Am J Roentgenol; 2008 Apr; 190(4):1097-104. PubMed ID: 18356461
[TBL] [Abstract][Full Text] [Related]
6. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
[TBL] [Abstract][Full Text] [Related]
7. Role of MRI for the diagnosis and prognosis of multiple myeloma.
Baur-Melnyk A; Buhmann S; Dürr HR; Reiser M
Eur J Radiol; 2005 Jul; 55(1):56-63. PubMed ID: 15950101
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
9. Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems.
Fechtner K; Hillengass J; Delorme S; Heiss C; Neben K; Goldschmidt H; Kauczor HU; Weber MA
Radiology; 2010 Oct; 257(1):195-204. PubMed ID: 20851941
[TBL] [Abstract][Full Text] [Related]
10. Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma.
Narquin S; Ingrand P; Azais I; Delwail V; Vialle R; Boucebci S; Tasu JP
Diagn Interv Imaging; 2013 Jun; 94(6):629-36. PubMed ID: 23683788
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
12. Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates.
Stäbler A; Baur A; Bartl R; Munker R; Lamerz R; Reiser MF
AJR Am J Roentgenol; 1996 Oct; 167(4):1029-36. PubMed ID: 8819407
[TBL] [Abstract][Full Text] [Related]
13. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
14. [Estimation of diffuse bone marrow infiltration of the spine in multiple myeloma: correlation of MRT with histological results].
Schmidt GP; Baur A; Stäbler A; Schoenberg SO; Steinborn M; Baltin V; Reiser MF
Rofo; 2005 May; 177(5):745-50. PubMed ID: 15871089
[TBL] [Abstract][Full Text] [Related]
15. Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging.
Squillaci E; Bolacchi F; Altobelli S; Franceschini L; Bergamini A; Cantonetti M; Simonetti G
Acta Radiol; 2015 Jun; 56(6):733-8. PubMed ID: 24973257
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
17. [Magnetic resonance tomography in plasmacytoma: ranking of various sequences in diffuse and focal infiltration patterns].
Baur A; Stäbler A; Steinborn M; Schnarkowski P; Pistitsch C; Lamerz R; Bartl R; Reiser M
Rofo; 1998 Apr; 168(4):323-9. PubMed ID: 9589093
[TBL] [Abstract][Full Text] [Related]
18. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
Dutoit JC; Vanderkerken MA; Verstraete KL
Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
[TBL] [Abstract][Full Text] [Related]
19. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
20. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
